Immix Biopharma announces publication of NXC-201 clinical results

Immix Biopharma (IMMX) announced the Journal of Clinical Oncology published NXC-201 clinical results in relapsed/refractory AL Amyloidosis. The data reported on 16 enrolled patients in NEXICART-1 who had received a median 4 prior lines of therapy prior to treatment with NXC-201. Results showed a complete response rate of 75%. Notably, findings demonstrated a favorable safety profile in frail relapsed/refractory AL Amyloidosis patients. Ex-U.S. study NEXICART-1 is the first NXC-201 clinical trial to treat relapsed/refractory AL Amyloidosis. “We are pleased that JCO has recognized the impact of NXC-201’s positive clinical results in relapsed/refractory AL Amyloidosis, where no FDA drugs are approved today,” said Ilya Rachman, CEO. “Building on these positive ex-U.S. results, our ongoing U.S. study is focused on relapsed/refractory AL Amyloidosis patients with preserved heart function, who we believe will benefit most from NXC-201 treatment.”